Surgery Partners' Idaho Falls Sales Tightens Core Strategy, RBC Says
MT Newswires Live
Sep 30
Surgery Partners' (SGRY) sale of its Idaho Falls facilities marks the company's most significant strategic move this year and leaves it more focused on its core short-stay care model, RBC Capital Markets said Tuesday in a report.
RBC cut its 2027 EBITDA guidance to $443 million from $580.9 million to reflect the divestiture.
The sale also provided around 30 basis points of balance-sheet improvement and stronger earnings-to-cash conversion, the report said.
RBC reiterated its outperform rating on Surgery Partners stock and its $19 price target.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.